Broad screening criteria of high-risk patients referred for technetium-99m-pyrophosphate (99mTc-PYP) scintigraphy led to a diagnosis of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in 23% of cases, according to a new study by a team of Canadian researchers.
“Our predictive tool may guide clinicians in refining pretest probability and optimizing diagnosis for ATTR-CM,” the researchers wrote in an article published in The Journal of the American College of Cardiology, Advances. “External validation in broader populations is warranted.”
To develop new screening criteria and a predictive tool to identify patients at high risk of ATTR-CM, the research team led by Margot K. Davis, MD, from the University of British Columbia in Canada conducted a prospective observational study at 2 academic sites in Vancouver between 2019 and 2022.